AT 56 | 2592

AT-56 is a selective, competitive, and highly bioavailable inhibitor of L-PGDS (lipocalin-type prostaglandin D synthase) (Ki = 75 µM). It inhibits the production of PGD2 by L-PGDS purified from human CSF and recombinant mouse cells with an IC₅₀ value of 95 µM. At concentrations as high as 100 µM in vitro or 30 mg/kg in vivo, AT-56 does not affect the production of PGE2, PGF2α, or H-PGDS-catalyzed PGD2.

AT-56 is a selective, competitive, and highly bioavailable inhibitor of L-PGDS (lipocalin-type prostaglandin D synthase) (Ki = 75 µM). It inhibits the production of PGD2 by L-PGDS purified from human CSF and recombinant mouse cells with an IC₅₀ value of 95 µM. At concentrations as high as 100 µM in vitro or 30 mg/kg in vivo, AT-56 does not affect the production of PGE2, PGF2α, or H-PGDS-catalyzed PGD2.

2592 | AT 56 DataSheet

Alternate Name/Synonyms: 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl)butyl]-piperidine

Appearance: White solid

Formulation: N/A

CAS Number: 162640-98-4

Structure Available?: Y

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₅H₂₇N₅

Molecular Weight: 397.52

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (>15 mg/ml)

Handling: Protect from light and air

Country of Origin: USA

Tag Line: A selective, competitive, and highly bioavailable inhibitor of L-PGDS (lipocalin-type prostaglandin D synthase)

MDL Number: N/A

PubChem CID: 11741525

SMILES: C1CN(CCC1=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CCCCC5=NNN=N5

InChi: InChI=1S/C25H27N5/c1-3-9-22-19(7-1)12-13-20-8-2-4-10-23(20)25(22)21-14-17-30(18-15-21)16-6-5-11-24-26-28-29-27-24/h1-4,7-10,12-13H,5-6,11,14-18H2,(H,26,27,28,29)

InChi Key: LQNGMDUIRLSESZ-UHFFFAOYSA-N